AEGLEA BIOTHERAPEUTICS, Inc.

805 Las Cimas Parkway

Suite 100

Austin, TX 78746

 

 

July 10, 2020

 

 

United States Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, DC 20549

 

Attention:Jeffrey Gabor

Office of Life Sciences

 

Re:Aeglea BioTherapeutics, Inc.

Registration Statement on Form S-3

Filed July 6, 2020

File No. 333-239706

 

Via EDGAR - Acceleration Request

Requested Date:July 14, 2020

 

Requested Time:4:00 p.m. Eastern Time

 

Ladies and Gentlemen:

Aeglea BioTherapeutics, Inc. (the “Registrant”) hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to make the above-captioned Registration Statement on Form S-3 effective at the “Requested Date” and “Requested Time” set forth above or as soon thereafter as practicable.

The Registrant hereby authorizes Robert A. Freedman or Ryan Mitteness, both of whom are attorneys with the Registrant’s outside legal counsel, Fenwick & West LLP, to orally modify or withdraw this request for acceleration.

 

 


 


 

Sincerely,

Aeglea BioTherapeutics, Inc.

 

By:  /s/ Charles N. York II

Charles N. York II
Chief Financial Officer

 

cc:

Anthony G. Quinn, Chief Executive Officer

Aeglea BioTherapeutics, Inc.

 

Robert A. Freedman, Esq.

Ryan Mitteness, Esq.

Fenwick & West LLP